Skip to main content

Decision Diagnostics Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average Volume3.75 million shs
Market Capitalization$4.25 million
P/E RatioN/A
Dividend YieldN/A

Receive DECN News and Ratings via Email

Sign-up to receive the latest news and ratings for Decision Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

About Decision Diagnostics

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides [email protected], an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.


See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTSMKTS
Industry Custom computer programming services
Phone805 446 1973
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Market Cap$4.25 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Decision Diagnostics (OTCMKTSMKTS:DECN) Frequently Asked Questions

What stocks does MarketBeat like better than Decision Diagnostics?

Wall Street analysts have given Decision Diagnostics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Decision Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Decision Diagnostics' key executives?

Decision Diagnostics' management team includes the following people:
  • Mr. Keith M. Berman, CEO, CFO, Sec. & Director (Age 68)
  • Mr. Mark Krakauer, Head of Genstrip Private Label Sales Efforts
  • Mr. Chris Knapp, Consultant

Who are some of Decision Diagnostics' key competitors?

What other stocks do shareholders of Decision Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Decision Diagnostics investors own include Genprex (GNPX), DiamondPeak (DPHC), Diffusion Pharmaceuticals (DFFN), Cypress Development (CYP), CytoDyn (CYDY), Cardiff Oncology (CRDF), (COCP), Caladrius Biosciences (CLBS), Churchill Capital Corp III (CCXX) and Brainstorm Cell Therapeutics (BCLI).

What is Decision Diagnostics' stock symbol?

Decision Diagnostics trades on the OTCMKTSMKTS under the ticker symbol "DECN."

How do I buy shares of Decision Diagnostics?

Shares of DECN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Decision Diagnostics make?

Decision Diagnostics has a market capitalization of $0.00.

How many employees does Decision Diagnostics have?

Decision Diagnostics employs 11 workers across the globe.

What is Decision Diagnostics' official website?

The official website for Decision Diagnostics is

How can I contact Decision Diagnostics?

The company can be reached via phone at 805 446 1973.

This page was last updated on 5/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.